nodes	percent_of_prediction	percent_of_DWPC	metapath
Atomoxetine—SLC6A3—bipolar disorder	0.243	0.31	CbGaD
Atomoxetine—HTR2C—bipolar disorder	0.22	0.28	CbGaD
Atomoxetine—SLC6A4—bipolar disorder	0.182	0.232	CbGaD
Atomoxetine—HTR2A—bipolar disorder	0.14	0.178	CbGaD
Atomoxetine—SLC6A2—locus ceruleus—bipolar disorder	0.00837	0.107	CbGeAlD
Atomoxetine—HTR2A—locus ceruleus—bipolar disorder	0.00503	0.064	CbGeAlD
Atomoxetine—HTR1B—telencephalic ventricle—bipolar disorder	0.00496	0.0631	CbGeAlD
Atomoxetine—SLC6A3—telencephalic ventricle—bipolar disorder	0.00492	0.0626	CbGeAlD
Atomoxetine—HTR1D—telencephalic ventricle—bipolar disorder	0.0048	0.0611	CbGeAlD
Atomoxetine—HTR2C—telencephalic ventricle—bipolar disorder	0.00476	0.0605	CbGeAlD
Atomoxetine—SLC6A2—autonomic nervous system—bipolar disorder	0.00445	0.0566	CbGeAlD
Atomoxetine—CYP2C19—urine—bipolar disorder	0.00341	0.0434	CbGeAlD
Atomoxetine—NPY1R—adrenal cortex—bipolar disorder	0.00283	0.036	CbGeAlD
Atomoxetine—HTR2A—autonomic nervous system—bipolar disorder	0.00267	0.034	CbGeAlD
Atomoxetine—HTR2A—telencephalic ventricle—bipolar disorder	0.00239	0.0304	CbGeAlD
Atomoxetine—HTR2A—urine—bipolar disorder	0.00218	0.0277	CbGeAlD
Atomoxetine—SLC6A4—blood plasma—bipolar disorder	0.00215	0.0273	CbGeAlD
Atomoxetine—CYP3A4—urine—bipolar disorder	0.00202	0.0257	CbGeAlD
Atomoxetine—CYP2D6—urine—bipolar disorder	0.00199	0.0253	CbGeAlD
Atomoxetine—NPY1R—thyroid gland—bipolar disorder	0.00197	0.0251	CbGeAlD
Atomoxetine—CYP2C19—blood plasma—bipolar disorder	0.00178	0.0227	CbGeAlD
Atomoxetine—NPY1R—nervous system—bipolar disorder	0.00166	0.0211	CbGeAlD
Atomoxetine—NPY1R—brain—bipolar disorder	0.00127	0.0161	CbGeAlD
Atomoxetine—HTR6—nervous system—bipolar disorder	0.00117	0.0148	CbGeAlD
Atomoxetine—HTR2A—blood plasma—bipolar disorder	0.00114	0.0145	CbGeAlD
Atomoxetine—CYP3A4—blood plasma—bipolar disorder	0.00105	0.0134	CbGeAlD
Atomoxetine—CYP2D6—blood plasma—bipolar disorder	0.00104	0.0132	CbGeAlD
Atomoxetine—HTR6—brain—bipolar disorder	0.000892	0.0113	CbGeAlD
Atomoxetine—HTR1B—nervous system—bipolar disorder	0.000704	0.00895	CbGeAlD
Atomoxetine—SLC6A3—nervous system—bipolar disorder	0.000698	0.00888	CbGeAlD
Atomoxetine—HTR1D—nervous system—bipolar disorder	0.000681	0.00866	CbGeAlD
Atomoxetine—HTR2C—nervous system—bipolar disorder	0.000674	0.00858	CbGeAlD
Atomoxetine—SLC6A3—cerebellum—bipolar disorder	0.000657	0.00835	CbGeAlD
Atomoxetine—SLC6A4—nervous system—bipolar disorder	0.000639	0.00813	CbGeAlD
Atomoxetine—SLC6A2—nervous system—bipolar disorder	0.000563	0.00716	CbGeAlD
Atomoxetine—HTR1B—brain—bipolar disorder	0.000538	0.00684	CbGeAlD
Atomoxetine—SLC6A3—brain—bipolar disorder	0.000533	0.00678	CbGeAlD
Atomoxetine—HTR1D—brain—bipolar disorder	0.000521	0.00662	CbGeAlD
Atomoxetine—HTR2C—brain—bipolar disorder	0.000516	0.00656	CbGeAlD
Atomoxetine—SLC6A4—brain—bipolar disorder	0.000489	0.00622	CbGeAlD
Atomoxetine—SLC6A2—brain—bipolar disorder	0.00043	0.00547	CbGeAlD
Atomoxetine—Orphenadrine—GRIN1—bipolar disorder	0.000419	0.0656	CrCbGaD
Atomoxetine—Reboxetine—HTR2C—bipolar disorder	0.000357	0.0558	CrCbGaD
Atomoxetine—HTR2A—nervous system—bipolar disorder	0.000338	0.0043	CbGeAlD
Atomoxetine—Diphenylpyraline—SLC6A3—bipolar disorder	0.000327	0.051	CrCbGaD
Atomoxetine—HTR2A—cerebellum—bipolar disorder	0.000318	0.00405	CbGeAlD
Atomoxetine—CYP3A4—nervous system—bipolar disorder	0.000313	0.00398	CbGeAlD
Atomoxetine—CYP2D6—nervous system—bipolar disorder	0.000308	0.00392	CbGeAlD
Atomoxetine—Duloxetine—SLC6A3—bipolar disorder	0.000304	0.0476	CrCbGaD
Atomoxetine—Reboxetine—SLC6A4—bipolar disorder	0.000296	0.0463	CrCbGaD
Atomoxetine—CYP2D6—cerebellum—bipolar disorder	0.00029	0.00369	CbGeAlD
Atomoxetine—Duloxetine—HTR2C—bipolar disorder	0.000275	0.0429	CrCbGaD
Atomoxetine—Protriptyline—SLC6A4—bipolar disorder	0.000272	0.0425	CrCbGaD
Atomoxetine—HTR2A—brain—bipolar disorder	0.000259	0.00329	CbGeAlD
Atomoxetine—Benzatropine—SLC6A3—bipolar disorder	0.00025	0.0391	CrCbGaD
Atomoxetine—Pseudoephedrine—MAOA—bipolar disorder	0.00025	0.0391	CrCbGaD
Atomoxetine—CYP2D6—brain—bipolar disorder	0.000236	0.003	CbGeAlD
Atomoxetine—Maprotiline—SLC6A3—bipolar disorder	0.000232	0.0362	CrCbGaD
Atomoxetine—Duloxetine—SLC6A4—bipolar disorder	0.000228	0.0356	CrCbGaD
Atomoxetine—Fluoxetine—HTR2C—bipolar disorder	0.000224	0.035	CrCbGaD
Atomoxetine—Pseudoephedrine—SLC6A3—bipolar disorder	0.000216	0.0337	CrCbGaD
Atomoxetine—Maprotiline—HTR2C—bipolar disorder	0.000209	0.0327	CrCbGaD
Atomoxetine—Fluoxetine—SLC6A4—bipolar disorder	0.000186	0.029	CrCbGaD
Atomoxetine—Modafinil—SLC6A3—bipolar disorder	0.000185	0.029	CrCbGaD
Atomoxetine—Duloxetine—HTR2A—bipolar disorder	0.000175	0.0273	CrCbGaD
Atomoxetine—Maprotiline—DRD2—bipolar disorder	0.000172	0.027	CrCbGaD
Atomoxetine—Pseudoephedrine—SLC6A4—bipolar disorder	0.000161	0.0252	CrCbGaD
Atomoxetine—Benzphetamine—SLC6A3—bipolar disorder	0.000161	0.0251	CrCbGaD
Atomoxetine—Fluoxetine—HTR2A—bipolar disorder	0.000143	0.0223	CrCbGaD
Atomoxetine—Maprotiline—HTR2A—bipolar disorder	0.000133	0.0208	CrCbGaD
Atomoxetine—Propranolol—HTR1A—bipolar disorder	0.000133	0.0207	CrCbGaD
Atomoxetine—Nortriptyline—HTR2C—bipolar disorder	0.000126	0.0196	CrCbGaD
Atomoxetine—Nortriptyline—HTR1A—bipolar disorder	0.000122	0.0191	CrCbGaD
Atomoxetine—Desipramine—SLC6A3—bipolar disorder	0.000115	0.0179	CrCbGaD
Atomoxetine—Nortriptyline—SLC6A4—bipolar disorder	0.000104	0.0163	CrCbGaD
Atomoxetine—Nortriptyline—DRD2—bipolar disorder	0.000104	0.0162	CrCbGaD
Atomoxetine—Desipramine—HTR2C—bipolar disorder	0.000104	0.0162	CrCbGaD
Atomoxetine—Desipramine—HTR1A—bipolar disorder	0.0001	0.0157	CrCbGaD
Atomoxetine—Desipramine—SLC6A4—bipolar disorder	8.58e-05	0.0134	CrCbGaD
Atomoxetine—Desipramine—DRD2—bipolar disorder	8.53e-05	0.0133	CrCbGaD
Atomoxetine—Nortriptyline—HTR2A—bipolar disorder	8.01e-05	0.0125	CrCbGaD
Atomoxetine—Desipramine—HTR2A—bipolar disorder	6.59e-05	0.0103	CrCbGaD
Atomoxetine—HTR1B—Signaling by GPCR—ADCY2—bipolar disorder	2.98e-05	0.00023	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling by GPCR—DRD2—bipolar disorder	2.95e-05	0.000227	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—DGKH—bipolar disorder	2.93e-05	0.000226	CbGpPWpGaD
Atomoxetine—HTR2C—GPCR downstream signaling—HTR1A—bipolar disorder	2.91e-05	0.000224	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism of lipids and lipoproteins—CLOCK—bipolar disorder	2.91e-05	0.000224	CbGpPWpGaD
Atomoxetine—CYP2C19—Biological oxidations—POMC—bipolar disorder	2.89e-05	0.000223	CbGpPWpGaD
Atomoxetine—HTR2C—GPCR downstream signaling—TAC1—bipolar disorder	2.87e-05	0.000221	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling by GPCR—ADM—bipolar disorder	2.85e-05	0.000219	CbGpPWpGaD
Atomoxetine—HTR2C—GPCR downstream signaling—DRD1—bipolar disorder	2.81e-05	0.000217	CbGpPWpGaD
Atomoxetine—HTR2A—Class A/1 (Rhodopsin-like receptors)—POMC—bipolar disorder	2.78e-05	0.000214	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling by GPCR—TSHB—bipolar disorder	2.77e-05	0.000214	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling by GPCR—TACR1—bipolar disorder	2.77e-05	0.000214	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling by GPCR—PDE4B—bipolar disorder	2.77e-05	0.000214	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—AKR1C4—bipolar disorder	2.76e-05	0.000213	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—TRPC3—bipolar disorder	2.76e-05	0.000212	CbGpPWpGaD
Atomoxetine—NPY1R—Signaling Pathways—GSK3B—bipolar disorder	2.74e-05	0.000211	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—TRPC3—bipolar disorder	2.73e-05	0.000211	CbGpPWpGaD
Atomoxetine—HTR2C—GPCR downstream signaling—DRD3—bipolar disorder	2.72e-05	0.00021	CbGpPWpGaD
Atomoxetine—NPY1R—Signaling Pathways—POMC—bipolar disorder	2.72e-05	0.00021	CbGpPWpGaD
Atomoxetine—NPY1R—Signaling Pathways—INS—bipolar disorder	2.7e-05	0.000208	CbGpPWpGaD
Atomoxetine—CYP3A4—Biological oxidations—COMT—bipolar disorder	2.69e-05	0.000207	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—DRD5—bipolar disorder	2.68e-05	0.000206	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—TRPC3—bipolar disorder	2.68e-05	0.000206	CbGpPWpGaD
Atomoxetine—CYP3A4—Biological oxidations—MAOA—bipolar disorder	2.67e-05	0.000206	CbGpPWpGaD
Atomoxetine—CYP2D6—Biological oxidations—POMC—bipolar disorder	2.66e-05	0.000205	CbGpPWpGaD
Atomoxetine—CYP3A4—Metapathway biotransformation—COMT—bipolar disorder	2.65e-05	0.000204	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling by GPCR—HTR1A—bipolar disorder	2.64e-05	0.000204	CbGpPWpGaD
Atomoxetine—HTR2C—GPCR downstream signaling—DRD4—bipolar disorder	2.64e-05	0.000204	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—ADM—bipolar disorder	2.63e-05	0.000203	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—RGS4—bipolar disorder	2.63e-05	0.000202	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—ADM—bipolar disorder	2.61e-05	0.000201	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling by GPCR—TAC1—bipolar disorder	2.6e-05	0.000201	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism—IMPA1—bipolar disorder	2.59e-05	0.000199	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—PDE4B—bipolar disorder	2.56e-05	0.000197	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—TSHB—bipolar disorder	2.56e-05	0.000197	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—TACR1—bipolar disorder	2.56e-05	0.000197	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—ADM—bipolar disorder	2.55e-05	0.000197	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling by GPCR—DRD1—bipolar disorder	2.55e-05	0.000197	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—DGKH—bipolar disorder	2.54e-05	0.000196	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—TSHB—bipolar disorder	2.54e-05	0.000196	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—PDE4B—bipolar disorder	2.54e-05	0.000196	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—TACR1—bipolar disorder	2.54e-05	0.000196	CbGpPWpGaD
Atomoxetine—HTR2A—GPCR downstream signaling—HTR1A—bipolar disorder	2.53e-05	0.000195	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism of lipids and lipoproteins—PIK3C2A—bipolar disorder	2.53e-05	0.000195	CbGpPWpGaD
Atomoxetine—HTR2A—GPCR downstream signaling—TAC1—bipolar disorder	2.49e-05	0.000192	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—PDE4B—bipolar disorder	2.49e-05	0.000192	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—TACR1—bipolar disorder	2.49e-05	0.000192	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—TSHB—bipolar disorder	2.49e-05	0.000192	CbGpPWpGaD
Atomoxetine—HTR2C—GPCR downstream signaling—ADCY2—bipolar disorder	2.49e-05	0.000192	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling by GPCR—DRD3—bipolar disorder	2.47e-05	0.000191	CbGpPWpGaD
Atomoxetine—HTR2C—GPCR downstream signaling—DRD2—bipolar disorder	2.46e-05	0.00019	CbGpPWpGaD
Atomoxetine—HTR2A—GPCR downstream signaling—HTR2C—bipolar disorder	2.44e-05	0.000188	CbGpPWpGaD
Atomoxetine—HTR2A—GPCR downstream signaling—DRD1—bipolar disorder	2.44e-05	0.000188	CbGpPWpGaD
Atomoxetine—HTR2C—GPCR ligand binding—POMC—bipolar disorder	2.44e-05	0.000188	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling by GPCR—DRD4—bipolar disorder	2.4e-05	0.000185	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—IMPA1—bipolar disorder	2.38e-05	0.000183	CbGpPWpGaD
Atomoxetine—HTR2A—GPCR downstream signaling—DRD3—bipolar disorder	2.36e-05	0.000182	CbGpPWpGaD
Atomoxetine—HTR6—GPCR downstream signaling—HTR2A—bipolar disorder	2.34e-05	0.00018	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—DRD5—bipolar disorder	2.32e-05	0.000179	CbGpPWpGaD
Atomoxetine—HTR1D—GPCR downstream signaling—HTR2A—bipolar disorder	2.32e-05	0.000179	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—IMPA2—bipolar disorder	2.3e-05	0.000177	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling by GPCR—HTR1A—bipolar disorder	2.3e-05	0.000177	CbGpPWpGaD
Atomoxetine—HTR2A—GPCR downstream signaling—DRD4—bipolar disorder	2.29e-05	0.000177	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—RGS4—bipolar disorder	2.28e-05	0.000176	CbGpPWpGaD
Atomoxetine—HTR1B—GPCR downstream signaling—HTR2A—bipolar disorder	2.28e-05	0.000175	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling by GPCR—TAC1—bipolar disorder	2.26e-05	0.000174	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling by GPCR—ADCY2—bipolar disorder	2.26e-05	0.000174	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling by GPCR—DRD2—bipolar disorder	2.24e-05	0.000172	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling by GPCR—HTR2C—bipolar disorder	2.22e-05	0.000171	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling by GPCR—DRD1—bipolar disorder	2.22e-05	0.000171	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism—NDUFV2—bipolar disorder	2.2e-05	0.000169	CbGpPWpGaD
Atomoxetine—HTR2A—GPCR downstream signaling—ADCY2—bipolar disorder	2.16e-05	0.000167	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling by GPCR—DRD3—bipolar disorder	2.15e-05	0.000165	CbGpPWpGaD
Atomoxetine—HTR2A—GPCR downstream signaling—DRD2—bipolar disorder	2.14e-05	0.000165	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism—AKR1C4—bipolar disorder	2.13e-05	0.000164	CbGpPWpGaD
Atomoxetine—HTR6—Signaling by GPCR—HTR2A—bipolar disorder	2.13e-05	0.000164	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—HTR1A—bipolar disorder	2.12e-05	0.000163	CbGpPWpGaD
Atomoxetine—HTR2A—GPCR ligand binding—POMC—bipolar disorder	2.12e-05	0.000163	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling by GPCR—HTR2A—bipolar disorder	2.11e-05	0.000163	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—HTR1A—bipolar disorder	2.1e-05	0.000162	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—TAC1—bipolar disorder	2.09e-05	0.000161	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling by GPCR—DRD4—bipolar disorder	2.08e-05	0.000161	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—TAC1—bipolar disorder	2.07e-05	0.00016	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling by GPCR—HTR2A—bipolar disorder	2.07e-05	0.000159	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—HTR1A—bipolar disorder	2.06e-05	0.000159	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—DRD1—bipolar disorder	2.05e-05	0.000158	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—HTR2C—bipolar disorder	2.05e-05	0.000158	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—HTR2C—bipolar disorder	2.03e-05	0.000157	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—DRD1—bipolar disorder	2.03e-05	0.000157	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—TAC1—bipolar disorder	2.03e-05	0.000156	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—TRPC3—bipolar disorder	2.03e-05	0.000156	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—NDUFV2—bipolar disorder	2.02e-05	0.000156	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—NTRK2—bipolar disorder	1.99e-05	0.000154	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—HTR2C—bipolar disorder	1.99e-05	0.000153	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—DRD1—bipolar disorder	1.99e-05	0.000153	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—DRD3—bipolar disorder	1.98e-05	0.000153	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—NTRK2—bipolar disorder	1.98e-05	0.000152	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—GSK3A—bipolar disorder	1.97e-05	0.000152	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—DRD3—bipolar disorder	1.97e-05	0.000152	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling by GPCR—ADCY2—bipolar disorder	1.96e-05	0.000151	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—GSK3A—bipolar disorder	1.96e-05	0.000151	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—AKR1C4—bipolar disorder	1.96e-05	0.000151	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling by GPCR—DRD2—bipolar disorder	1.94e-05	0.00015	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—NTRK2—bipolar disorder	1.94e-05	0.000149	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—ADM—bipolar disorder	1.94e-05	0.000149	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—DRD3—bipolar disorder	1.93e-05	0.000149	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—DRD4—bipolar disorder	1.93e-05	0.000148	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—GSK3A—bipolar disorder	1.92e-05	0.000148	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism—NR1D1—bipolar disorder	1.91e-05	0.000147	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—DRD4—bipolar disorder	1.91e-05	0.000147	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—TSHB—bipolar disorder	1.89e-05	0.000145	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—PDE4B—bipolar disorder	1.89e-05	0.000145	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—TACR1—bipolar disorder	1.89e-05	0.000145	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—DRD4—bipolar disorder	1.87e-05	0.000144	CbGpPWpGaD
Atomoxetine—HTR6—GPCR downstream signaling—POMC—bipolar disorder	1.87e-05	0.000144	CbGpPWpGaD
Atomoxetine—HTR1D—GPCR downstream signaling—POMC—bipolar disorder	1.86e-05	0.000143	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism—NCAN—bipolar disorder	1.83e-05	0.000141	CbGpPWpGaD
Atomoxetine—HTR1B—GPCR downstream signaling—POMC—bipolar disorder	1.82e-05	0.00014	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—ADCY2—bipolar disorder	1.81e-05	0.00014	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—TCF7L2—bipolar disorder	1.81e-05	0.000139	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—ADCY2—bipolar disorder	1.8e-05	0.000139	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—DRD2—bipolar disorder	1.79e-05	0.000138	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—TCF7L2—bipolar disorder	1.79e-05	0.000138	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism—SLC5A3—bipolar disorder	1.79e-05	0.000138	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—DRD2—bipolar disorder	1.78e-05	0.000137	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—TRPC3—bipolar disorder	1.76e-05	0.000136	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—ADCY2—bipolar disorder	1.76e-05	0.000136	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—NR1D1—bipolar disorder	1.76e-05	0.000136	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—TCF7L2—bipolar disorder	1.75e-05	0.000135	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—DRD2—bipolar disorder	1.74e-05	0.000134	CbGpPWpGaD
Atomoxetine—CYP3A4—Biological oxidations—POMC—bipolar disorder	1.74e-05	0.000134	CbGpPWpGaD
Atomoxetine—HTR2C—GPCR downstream signaling—HTR2A—bipolar disorder	1.72e-05	0.000133	CbGpPWpGaD
Atomoxetine—HTR6—Signaling by GPCR—POMC—bipolar disorder	1.7e-05	0.000131	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling by GPCR—POMC—bipolar disorder	1.69e-05	0.00013	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—NCAN—bipolar disorder	1.68e-05	0.00013	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—ADM—bipolar disorder	1.68e-05	0.00013	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling by GPCR—POMC—bipolar disorder	1.65e-05	0.000127	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—SLC5A3—bipolar disorder	1.65e-05	0.000127	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—PDE4B—bipolar disorder	1.64e-05	0.000126	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—TSHB—bipolar disorder	1.64e-05	0.000126	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—TACR1—bipolar disorder	1.64e-05	0.000126	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—NTRK1—bipolar disorder	1.62e-05	0.000125	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—NTRK1—bipolar disorder	1.61e-05	0.000124	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—S100B—bipolar disorder	1.58e-05	0.000122	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—NTRK1—bipolar disorder	1.58e-05	0.000122	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—S100B—bipolar disorder	1.57e-05	0.000121	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling by GPCR—HTR2A—bipolar disorder	1.57e-05	0.000121	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—HTR1A—bipolar disorder	1.56e-05	0.00012	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—IMPA1—bipolar disorder	1.55e-05	0.00012	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—TAC1—bipolar disorder	1.54e-05	0.000119	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—S100B—bipolar disorder	1.53e-05	0.000118	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—DRD1—bipolar disorder	1.51e-05	0.000116	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—NTRK2—bipolar disorder	1.47e-05	0.000113	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—DRD3—bipolar disorder	1.46e-05	0.000113	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—GSK3A—bipolar disorder	1.45e-05	0.000112	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—DRD4—bipolar disorder	1.42e-05	0.000109	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—NRG1—bipolar disorder	1.39e-05	0.000107	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—NRG1—bipolar disorder	1.38e-05	0.000107	CbGpPWpGaD
Atomoxetine—HTR2C—GPCR downstream signaling—POMC—bipolar disorder	1.38e-05	0.000106	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—HTR1A—bipolar disorder	1.36e-05	0.000105	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—NRG1—bipolar disorder	1.35e-05	0.000104	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—TAC1—bipolar disorder	1.34e-05	0.000103	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—ADCY2—bipolar disorder	1.33e-05	0.000103	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—TCF7L2—bipolar disorder	1.33e-05	0.000103	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—NDUFV2—bipolar disorder	1.32e-05	0.000102	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—DRD2—bipolar disorder	1.32e-05	0.000102	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—DRD1—bipolar disorder	1.31e-05	0.000101	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—HTR2C—bipolar disorder	1.31e-05	0.000101	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism—CLOCK—bipolar disorder	1.3e-05	9.99e-05	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—AKR1C4—bipolar disorder	1.28e-05	9.87e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—NTRK2—bipolar disorder	1.27e-05	9.82e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—DRD3—bipolar disorder	1.27e-05	9.78e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—GSK3A—bipolar disorder	1.26e-05	9.73e-05	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism—TPH2—bipolar disorder	1.26e-05	9.73e-05	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism—TSHB—bipolar disorder	1.26e-05	9.73e-05	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism—CACNB2—bipolar disorder	1.26e-05	9.73e-05	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—HTR2A—bipolar disorder	1.26e-05	9.68e-05	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling by GPCR—POMC—bipolar disorder	1.25e-05	9.64e-05	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—HTR2A—bipolar disorder	1.25e-05	9.61e-05	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism—DPYD—bipolar disorder	1.24e-05	9.58e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—DRD4—bipolar disorder	1.23e-05	9.49e-05	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—HTR2A—bipolar disorder	1.22e-05	9.41e-05	CbGpPWpGaD
Atomoxetine—HTR2A—GPCR downstream signaling—POMC—bipolar disorder	1.2e-05	9.22e-05	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—NTRK1—bipolar disorder	1.2e-05	9.22e-05	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—CLOCK—bipolar disorder	1.19e-05	9.19e-05	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—S100B—bipolar disorder	1.16e-05	8.96e-05	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—TSHB—bipolar disorder	1.16e-05	8.95e-05	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—TPH2—bipolar disorder	1.16e-05	8.95e-05	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—CACNB2—bipolar disorder	1.16e-05	8.95e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—ADCY2—bipolar disorder	1.16e-05	8.93e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—TCF7L2—bipolar disorder	1.15e-05	8.9e-05	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism—CACNA1C—bipolar disorder	1.15e-05	8.9e-05	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—NR1D1—bipolar disorder	1.15e-05	8.86e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—DRD2—bipolar disorder	1.15e-05	8.84e-05	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—DPYD—bipolar disorder	1.14e-05	8.81e-05	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism—PIK3C2A—bipolar disorder	1.13e-05	8.67e-05	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism of lipids and lipoproteins—POMC—bipolar disorder	1.11e-05	8.56e-05	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—NCAN—bipolar disorder	1.1e-05	8.48e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling by GPCR—POMC—bipolar disorder	1.09e-05	8.37e-05	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—SLC5A3—bipolar disorder	1.08e-05	8.31e-05	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—CACNA1C—bipolar disorder	1.06e-05	8.19e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—NTRK1—bipolar disorder	1.04e-05	8e-05	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—PIK3C2A—bipolar disorder	1.04e-05	7.98e-05	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—NRG1—bipolar disorder	1.03e-05	7.91e-05	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—GSK3B—bipolar disorder	1.01e-05	7.8e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—S100B—bipolar disorder	1.01e-05	7.78e-05	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism—SNAP25—bipolar disorder	1.01e-05	7.78e-05	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—GSK3B—bipolar disorder	1e-05	7.74e-05	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—POMC—bipolar disorder	1e-05	7.73e-05	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—INS—bipolar disorder	9.98e-06	7.69e-05	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—POMC—bipolar disorder	9.96e-06	7.67e-05	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—INS—bipolar disorder	9.9e-06	7.63e-05	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—GSK3B—bipolar disorder	9.83e-06	7.58e-05	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—POMC—bipolar disorder	9.75e-06	7.51e-05	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—INS—bipolar disorder	9.69e-06	7.47e-05	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—SNAP25—bipolar disorder	9.28e-06	7.16e-05	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—HTR2A—bipolar disorder	9.25e-06	7.13e-05	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism—ADCY2—bipolar disorder	8.93e-06	6.89e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—NRG1—bipolar disorder	8.91e-06	6.87e-05	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—ADCY2—bipolar disorder	8.22e-06	6.33e-05	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—CLOCK—bipolar disorder	7.79e-06	6.01e-05	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism—COMT—bipolar disorder	7.65e-06	5.9e-05	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism—MAOA—bipolar disorder	7.6e-06	5.86e-05	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—TPH2—bipolar disorder	7.59e-06	5.85e-05	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—TSHB—bipolar disorder	7.59e-06	5.85e-05	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—CACNB2—bipolar disorder	7.59e-06	5.85e-05	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—DPYD—bipolar disorder	7.47e-06	5.76e-05	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—GSK3B—bipolar disorder	7.45e-06	5.74e-05	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—POMC—bipolar disorder	7.39e-06	5.69e-05	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—INS—bipolar disorder	7.35e-06	5.66e-05	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—COMT—bipolar disorder	7.04e-06	5.42e-05	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—MAOA—bipolar disorder	6.99e-06	5.39e-05	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—CACNA1C—bipolar disorder	6.94e-06	5.35e-05	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—PIK3C2A—bipolar disorder	6.77e-06	5.22e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—GSK3B—bipolar disorder	6.47e-06	4.99e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—POMC—bipolar disorder	6.42e-06	4.95e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—INS—bipolar disorder	6.38e-06	4.92e-05	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism—MTHFR—bipolar disorder	6.18e-06	4.77e-05	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—SNAP25—bipolar disorder	6.07e-06	4.68e-05	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—MTHFR—bipolar disorder	5.69e-06	4.38e-05	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—ADCY2—bipolar disorder	5.37e-06	4.14e-05	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism—POMC—bipolar disorder	4.94e-06	3.81e-05	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism—INS—bipolar disorder	4.92e-06	3.79e-05	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—COMT—bipolar disorder	4.6e-06	3.55e-05	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—MAOA—bipolar disorder	4.57e-06	3.52e-05	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—POMC—bipolar disorder	4.55e-06	3.51e-05	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—INS—bipolar disorder	4.52e-06	3.49e-05	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—MTHFR—bipolar disorder	3.72e-06	2.87e-05	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—POMC—bipolar disorder	2.97e-06	2.29e-05	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—INS—bipolar disorder	2.96e-06	2.28e-05	CbGpPWpGaD
